Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
Well if you’ve looked into this at all you’d see people CANNOT. Hypothetically people can, but in reality, people can only lose weight short term and then they gain it back.
You’re arguing a point that has no evidence beyond “well I personally think it SHOULD work like this!”